Antibodies to Citrullinated Protein Antigens, Rheumatoid Factor Isotypes and the Shared Epitope and the Near-Term Development of Clinically-Apparent Rheumatoid Arthritis.

Autor:	Bergstedt DT; Department of Medicine, St. Joseph's Hospital, SCL Health, Denver, CO, United States.; Division of Rheumatology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, United States., Tarter WJ; Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado-Denver Anschutz Medical Campus, Aurora, CO, United States., Peterson RA; Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado-Denver Anschutz Medical Campus, Aurora, CO, United States., Feser ML; Division of Rheumatology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, United States., Parish MC; Division of Rheumatology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, United States., Striebich CC; Division of Rheumatology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, United States., Demoruelle MK; Division of Rheumatology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, United States., Moss L; Division of Rheumatology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, United States., Bemis EA; Division of Rheumatology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, United States., Norris JM; Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, United States., Holers VM; Division of Rheumatology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, United States., Edison JD; Department of Medicine, Walter Reed National Military Medical Center, Bethesda, MD, United States., Thiele GM; University of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Omaha, NE, United States., Mikuls TR; University of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Omaha, NE, United States., Deane KD; Division of Rheumatology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2022 Jun 22; Vol. 13, pp. 916277. Date of Electronic Publication: 2022 Jun 22 (Print Publication: 2022).
DOI:	10.3389/fimmu.2022.916277
Abstrakt:	Background/purpose: In rheumatoid arthritis (RA) autoantibodies including antibodies to citrullinated protein antigens (ACPA) and rheumatoid factor (RF) can be predictive of incident clinical RA. However, there is limited understanding of how antibody changes over time impact prediction of the likelihood and timing of future clinical RA. Materials and Methods: We evaluated relationships between ACPA, the shared epitope (SE), RF isotypes and incident RA in a prospective cohort of 90 ACPA(+) individuals without baseline arthritis identified through health-fair testing (i.e. Healthfair). We also evaluated ACPA and RF isotypes and time-to-diagnosis of RA in a retrospective cohort of 215 individuals with RA from the Department of Defense Serum Repository (DoDSR). Results: Twenty-six of 90 (29%) of ACPA(+) Healthfair participants developed incident RA. Baseline or incident dual RF-IgA and RF-IgM positivity was associated with increased risk for incident RA (HR 3.09; 95% CI 1.15 to 8.29) although RFs were negative in ~50% of individuals with incident RA. SE was associated with increased risk of RA (HR 2.87, 95% CI 1.22-6.76). In the DoDSR cohort, triple positivity for ACPA, RF-IgA and RF-IgM was present a median of 1-2 years prior to RA diagnosis, with some sex-specific differences. Conclusion: These findings can be used to counsel individuals at-risk for future RA and to design clinical trials for RA prevention. The findings also suggest that RF could be a surrogate outcome as a success of an immunologic intervention in RA prevention. Additional studies are needed to understand the biologic of different patterns of autoantibody elevations in RA evolution. Competing Interests: KD has received free materials for autoantibody testing from Inova Diagnostics, Inc., and he has also served as an advisor for Inova Diagnostics, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Bergstedt, Tarter, Peterson, Feser, Parish, Striebich, Demoruelle, Moss, Bemis, Norris, Holers, Edison, Thiele, Mikuls and Deane.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu